17th World Conference on Lung Cancer
2016; Elsevier BV; Volume: 18; Issue: 1 Linguagem: Inglês
10.1016/s1470-2045(16)30634-9
ISSN1474-5488
Autores Tópico(s)Synthesis and biological activity
ResumoEpitinib, a new EGFR tyrosine kinase inhibitor (TKI) developed specifically to improve brain penetration, is active against brain metastases in EGFR-mutant NSCLC according to Chinese researchers after an interim analysis of 27 patients enrolled in an ongoing phase 1 trial. Qing Zhou (Guangdong, Guangzhou, China) and colleagues enrolled patients with confirmed intracranial lesions to receive oral epitinib (160 mg per day) irrespective of previous TKI usage. Most frequent adverse events included skin rash (89%), hyperpigmentation (41%), and diarrhoea (30%). Seven of 13 previously untreated patients achieved a partial response, and two of five previously untreated patients with brain metastases greater than 10 mm in diameter achieved intracranial partial responses. Responses were not seen in patients who had received previous TKI therapy.
Referência(s)